CORT240621C21000
- 7.97
- 0.000.00%
Corcept Therapeutics Newsroom
Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficu
Express News | Corcept Therapeutics Inc - Results Demonstrate a Hypercortisolism Prevalence Rate of 24 Percent in This Patient Population
Express News | Corcept Announces Presentation of Results From Prevalence Phase of Catalyst Clinical Trial at American Diabetes Association’s Scientific Sessions
What Makes Corcept Therapeutics (CORT) a Good Investment Bet?
6 Analysts Have This To Say About Corcept Therapeutics
During the last three months, 6 analysts shared their evaluations of Corcept Therapeutics (NASDAQ:CORT), revealing diverse outlooks from bullish to bearish.The table below provides a snapshot of their
Corcept Therapeutics Is Maintained at Buy by Truist Securities
Corcept Therapeutics Is Maintained at Buy by Truist Securities
Corcept Therapeutics Insiders Sold US$1.6m Of Shares Suggesting Hesitancy
Many Corcept Therapeutics Incorporated (NASDAQ:CORT) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insiders are buying is u
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $65
Truist Financial analyst Joon Lee maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 48.3%
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $65
Truist Financial analyst Joon Lee maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and sets the target price at $65.According to TipRanks data, the analyst has a success rate of 48.3% and
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for
Teva Pharmaceutical Sues Corcept Therapeutics, Down 8%, Alleging Market Monopolization for Cushing's Syndrome Drug Korlym
Teva Pharmaceutical Industries (TEVA) has sued Corcept Therapeutics (CORT), accusing the company of monopolizing the market for Korlym, a mifepristone-based drug used to treat Cushing's syndrome, acco
Express News | Corcept Therapeutics Shares Are Trading Lower Following a Report Suggesting Teva Has Sued the Company, Accusing It of a Monopoly on Korlym
Express News | Reported Late Thursday: Teva Sues Corcept Over Mifepristone 'Monopoly' For Rare Disorder
Corcept Therapeutics (CORT) Is a Top-Ranked Momentum Stock: Should You Buy?
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $35
Piper Sandler analyst David Amsellem maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 42
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Corcept Therapeutics(CORT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.3% and a total average return of 23.0% ov
Insider Sale: Chief Development Officer William Guyer Sells 10,000 Shares of Corcept ...
Corcept Therapeutics(CORT.US) Director Sells US$66,462 in Common Stock
$Corcept Therapeutics(CORT.US)$ Director Swisher Daniel N JR sold 2,200 shares of common stock on Jun 3, 2024 at an average price of $30.21 for a total value of $66,462.Source: Announcement What is st
Corcept Therapeutics(CORT.US) Officer Sells US$320K in Common Stock
$Corcept Therapeutics(CORT.US)$ Officer Guyer William sold 10,000 shares of common stock on Jun 3, 2024 at an average price of $32 for a total value of $320K.Source: Announcement What is statement of
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $38
CCORF analyst Edward Nash maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 40.9% and a t